Pdb77 - Long-Term Cost-Effectiveness Analysis of Ideglira Versus Iglarlixi for the Treatment of Patients With Poorly Controlled Type 2 Diabetes on Basal Insulin in the Italian Setting

Montagnoli, Roberta; Lastoria, Giusi; Parekh, Witesh; Pöhlmann, Johannes; Hunt, Barnaby

doi:10.1016/j.jval.2018.09.782

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The long-term cost-effectiveness of insulin degludec/ liraglutide versus insulin glargine/lixisenatide in patients with T2D poorly controlled with basal insulin in the EU has been evaluated in pharmacoeconomic analyses from the healthcare payer perspectives of Italy [50], Denmark [51] and the Czech Republic [52] (year of costing 2018 in all analyses). They suggest that, over patient lifetimes, insulin degludec/liraglutide is cost-effective relative to insulin glargine/lixisenatide, with insulin degludec/liraglutide being more costly, but providing greater gains in quality-adjusted life-years (QALYs); the incremental costs per QALY gained were EUR7386 [50], DKK182,451 [51] and CZK695,998 or CZK348,323 (depending on whether the insulin glargine/ lixisenatide pen contained 33 or 50 µg/mL of lixisenatide) [52]. Further EU cost-effectiveness analyses for insulin glargine/lixisenatide would be beneficial (given the considerable societal and healthcare payer costs associated with T2D), as would longer-term clinical experience.…”

Section: What Is the Current Clinical Position Of Insulin Glargine/limentioning

confidence: 99%

Insulin glargine/lixisenatide in type 2 diabetes: a profile of its use

Deeks

2019

Drugs Ther Perspect

View full text Add to dashboard Cite

Subcutaneous insulin glargine/lixisenatide [Suliqua ® 100/33 and 100/50 (EU); Soliqua ® 100/33 (USA)] is a titratable, fixedratio combination of a long-acting basal insulin analogue + a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to treat inadequately controlled type 2 diabetes (T2D) in adults. Once-daily insulin glargine/lixisenatide provided glycaemic control better than that of insulin glargine or lixisenatide in insulin-naive patients (when added to metformin) and better than that of insulin glargine in insulin-experienced patients (when used ± metformin) in phase 3 trials in adults with inadequately controlled T2D. It also had a beneficial effect on bodyweight and did not increase the frequency of hypoglycaemia versus insulin glargine. Insulin glargine/lixisenatide is generally well tolerated and offers the convenience of once-daily administration of two subcutaneous antihyperglycaemic agents. It is, therefore, a valuable option for improving glycaemic control in adults with T2D when this has not been provided by metformin alone or metformin + another oral antihyperglycaemic agent or + basal insulin. Adis evaluation of insulin glargine/lixisenatide in the treatment of T2DOnce-daily fixed-ratio combination of a long-acting insulin analogue (insulin glargine) + a GLP-1 RA (lixisenatide)Titratable to meet the insulin needs of the individual patient Provides better glycaemic control as an add-on to metformin than insulin glargine or lixisenatide in insulinnaive patients Provides better glycaemic control than insulin glargine, when used ± metformin, in insulin-experienced patients Does not increase hypoglycaemic risk vs insulin glargineSafety profile is generally consistent with its components Additional information for this Adis Drug Q&A can be found at https ://doi.org/10.6084/m9.figsh are.96963 38.

show abstract